To Örebro University

oru.seÖrebro University Publications
Change search
Link to record
Permanent link

Direct link
Salihovic, Samira, Associate Senior LecturerORCID iD iconorcid.org/0000-0001-5752-4196
Alternative names
Publications (10 of 101) Show all publications
Salihovic, S., Dunder, L., Lind, M. & Lind, L. (2024). Assessing the performance of a targeted absolute quantification isotope dilution liquid chromatograhy tandem mass spectrometry assay versus a commercial nontargeted relative quantification assay for detection of three major perfluoroalkyls in human blood. Journal of Mass Spectrometry, 59(2), Article ID e4999.
Open this publication in new window or tab >>Assessing the performance of a targeted absolute quantification isotope dilution liquid chromatograhy tandem mass spectrometry assay versus a commercial nontargeted relative quantification assay for detection of three major perfluoroalkyls in human blood
2024 (English)In: Journal of Mass Spectrometry, ISSN 1076-5174, E-ISSN 1096-9888, Vol. 59, no 2, article id e4999Article in journal (Refereed) Published
Abstract [en]

Isotope dilution ultrahigh-performance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) is commonly used for trace analysis of polyfluoroalkyl and perfluoroalkyl substances (PFAS) in difficult matrices. Commercial nontargeted analysis of major PFAS where relative concentrations are obtained cost effectively is rapidly emerging and is claimed to provide comparable results to that of absolute quantification using matrix matched calibration and isotope dilution UHPLC-MS/MS. However, this remains to be demonstrated on a large scale. We aimed to assess the performance of a targeted absolute quantification isotope dilution LC-MS/MS assay versus a commercial nontargeted relative quantification assay for detection of three major PFAS in human blood. We evaluated a population-based cohort of 503 individuals. Correlations were assessed using Spearman's rank correlation coefficients (rho). Precision and bias were assessed using Bland-Altman plots. For perfluorooctane sulfonic acid, the median concentrations were 5.10 ng/mL (interquartile range [IQR] 3.50-7.24 ng/mL), the two assays correlated with rho 0.83. For perfluorooctanoic acid, the median concentrations were 2.14 ng/mL (IQR 1.60-3.0 ng/mL), the two assays correlated with rho 0.92. For perfluorohexanesulfonate, the median concentrations were 5.5 ng/mL (IQR 2.50-11.61 ng/mL), the two assays correlated with rho 0.96. The Bland-Altman statistical test showed agreement of the mean difference for the majority of samples (97-98%) between the two assays. Absolute plasma concentrations of PFAS obtained using matrix matched calibration and isotope dilution UHPLC-MS/MS show agreement with relative plasma concentrations from a nontargeted commercial platform by Metabolon. We observed striking consistency between the two assays when examining the associations of the three PFAS with cholesterol, offering additional confidence in the validity of utilizing the nontargeted approach for correlations with various health phenotypes.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
PFAS, cholesterol, isotope dilution, mass spectrometry, metabolon, nontargeted, targeted
National Category
Analytical Chemistry Occupational Health and Environmental Health
Identifiers
urn:nbn:se:oru:diva-111039 (URN)10.1002/jms.4999 (DOI)001147311100001 ()38263897 (PubMedID)2-s2.0-85182814684 (Scopus ID)
Funder
Swedish Research Council Formas, 2015-756
Available from: 2024-01-30 Created: 2024-01-30 Last updated: 2024-02-02Bibliographically approved
Hyötyläinen, T., McGlinchey, A. J., Salihovic, S., Schubert, A., Douglas, A., Hay, D. C., . . . Oresic, M. (2024). In utero exposures to perfluoroalkyl substances and the human fetal liver metabolome in Scotland: a cross-sectional study. The Lancet Planetary Health, 8(1), e5-e17
Open this publication in new window or tab >>In utero exposures to perfluoroalkyl substances and the human fetal liver metabolome in Scotland: a cross-sectional study
Show others...
2024 (English)In: The Lancet Planetary Health, E-ISSN 2542-5196, Vol. 8, no 1, p. e5-e17Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Perfluoroalkyl and polyfluoroalkyl substances are classed as endocrine disrupting compounds but continue to be used in many products such as firefighting foams, flame retardants, utensil coatings, and waterproofing of food packaging. Perfluoroalkyl exposure aberrantly modulates lipid, metabolite, and bile acid levels, increasing susceptibility to onset and severity of metabolic diseases, such as diabetes and metabolic dysfunction-associated steatotic liver disease. To date, most studies in humans have focused on perfluoroalkyl-exposure effects in adults. In this study we aimed to show if perfluoroalkyls are present in the human fetal liver and if they have metabolic consequences for the human fetus.

METHODS: In this cross-sectional study, human fetal livers from elective termination of pregnancies at the Aberdeen Pregnancy Counselling Service, Aberdeen, UK, were analysed by both targeted (bile acids and perfluoroalkyl substances) and combined targeted and untargeted (lipids and polar metabolites) mass spectrometry based metabolomic analyses, as well as with RNA-Seq. Only fetuses from normally progressing pregnancies (determined at ultrasound scan before termination), terminated for non-medical reasons, from women older than 16 years, fluent in English, and between 11 and 21 weeks of gestation were collected. Women exhibiting considerable emotional distress or whose fetuses had anomalies identified at ultrasound scan were excluded. Stringent bioinformatic and statistical methods such as partial correlation network analysis, linear regression, and pathway analysis were applied to this data to investigate the association of perfluoroalkyl exposure with hepatic metabolic pathways.

FINDINGS: Fetuses included in this study were collected between Dec 2, 2004, and Oct 27, 2014. 78 fetuses were included in the study: all 78 fetuses were included in the metabolomics analysis (40 female and 38 male) and 57 fetuses were included in the RNA-Seq analysis (28 female and 29 male). Metabolites associated with perfluoroalkyl were identified in the fetal liver and these varied with gestational age. Conjugated bile acids were markedly positively associated with fetal age. 23 amino acids, fatty acids, and sugar derivatives in fetal livers were inversely associated with perfluoroalkyl exposure, and the bile acid glycolithocholic acid was markedly positively associated with all quantified perfluoroalkyl. Furthermore, 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis rate, was strongly positively associated with perfluoroalkyl levels and was detectable as early as gestational week 12.

INTERPRETATION: Our study shows direct evidence for the in utero effects of perfluoroalkyl exposure on specific key hepatic products. Our results provide evidence that perfluoroalkyl exposure, with potential future consequences, manifests in the human fetus as early as the first trimester of gestation. Furthermore, the profiles of metabolic changes resemble those observed in perinatal perfluoroalkyl exposures. Such exposures are already linked with susceptibility, initiation, progression, and exacerbation of a wide range of metabolic diseases.

Place, publisher, year, edition, pages
Elsevier, 2024
National Category
Occupational Health and Environmental Health
Identifiers
urn:nbn:se:oru:diva-110658 (URN)10.1016/S2542-5196(23)00257-7 (DOI)001158718400001 ()38199723 (PubMedID)2-s2.0-85181938990 (Scopus ID)
Funder
EU, Horizon EuropeEU, FP7, Seventh Framework ProgrammeSwedish Research CouncilSwedish Research Council FormasNovo Nordisk FoundationAcademy of Finland
Note

FUNDING: UK Medical Research Council, Horizon Europe Program of the European Union, Seventh Framework Programme of the European Union, NHS Grampian Endowments grants, European Partnership for the Assessment of Risks from Chemicals, Swedish Research Council, Formas, Novo Nordisk Foundation, and the Academy of Finland.

Available from: 2024-01-11 Created: 2024-01-11 Last updated: 2024-02-20Bibliographically approved
Mathisen, C.-W. B., Nyström, N., Bazov, I., Andersen, S., Olbjørn, C., Perminow, G., . . . Halfvarson, J. (2023). A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts. Paper presented at 8th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. Journal of Crohn's & Colitis, 17(Suppl. 1), I71-I73, Article ID DOP11.
Open this publication in new window or tab >>A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
Show others...
2023 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 17, no Suppl. 1, p. I71-I73, article id DOP11Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2023
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-107213 (URN)000960367600052 ()
Conference
8th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023
Available from: 2023-07-31 Created: 2023-07-31 Last updated: 2023-07-31Bibliographically approved
Alijagic, A., Scherbak, N., Kotlyar, O., Karlsson, P., Wang, X., Odnevall, I., . . . Engwall, M. (2023). A Novel Nanosafety Approach Using Cell Painting, Metabolomics, and Lipidomics Captures the Cellular and Molecular Phenotypes Induced by the Unintentionally Formed Metal-Based (Nano)Particles. Cells, 12(2), Article ID 281.
Open this publication in new window or tab >>A Novel Nanosafety Approach Using Cell Painting, Metabolomics, and Lipidomics Captures the Cellular and Molecular Phenotypes Induced by the Unintentionally Formed Metal-Based (Nano)Particles
Show others...
2023 (English)In: Cells, E-ISSN 2073-4409, Vol. 12, no 2, article id 281Article in journal (Refereed) Published
Abstract [en]

Additive manufacturing (AM) or industrial 3D printing uses cutting-edge technologies and materials to produce a variety of complex products. However, the effects of the unintentionally emitted AM (nano)particles (AMPs) on human cells following inhalation, require further investigations. The physicochemical characterization of the AMPs, extracted from the filter of a Laser Powder Bed Fusion (L-PBF) 3D printer of iron-based materials, disclosed their complexity, in terms of size, shape, and chemistry. Cell Painting, a high-content screening (HCS) assay, was used to detect the subtle morphological changes elicited by the AMPs at the single cell resolution. The profiling of the cell morphological phenotypes, disclosed prominent concentration-dependent effects on the cytoskeleton, mitochondria, and the membranous structures of the cell. Furthermore, lipidomics confirmed that the AMPs induced the extensive membrane remodeling in the lung epithelial and macrophage co-culture cell model. To further elucidate the biological mechanisms of action, the targeted metabolomics unveiled several inflammation-related metabolites regulating the cell response to the AMP exposure. Overall, the AMP exposure led to the internalization, oxidative stress, cytoskeleton disruption, mitochondrial activation, membrane remodeling, and metabolic reprogramming of the lung epithelial cells and macrophages. We propose the approach of integrating Cell Painting with metabolomics and lipidomics, as an advanced nanosafety methodology, increasing the ability to capture the cellular and molecular phenotypes and the relevant biological mechanisms to the (nano)particle exposure.

Place, publisher, year, edition, pages
MDPI, 2023
Keywords
Additive manufacturing, high-content screening (HCS), inflammation, multivariate analysis, nanoparticle emissions, new approach methodologies (NAMs), targeted metabolomics
National Category
Cell and Molecular Biology
Identifiers
urn:nbn:se:oru:diva-103319 (URN)10.3390/cells12020281 (DOI)000916977400001 ()36672217 (PubMedID)2-s2.0-85146736511 (Scopus ID)
Note

Funding agency:

General Electric 20190107 20160019

Available from: 2023-01-23 Created: 2023-01-23 Last updated: 2023-02-14Bibliographically approved
Bazov, I., Kruse, R., Bergemalm, D., Eriksson, C., Hedin, C. R., Carlson, M., . . . Halfvarson, J. (2023). A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts. Paper presented at 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. Journal of Crohn's & Colitis, 17(Suppl. 1), I314-I315, Article ID P154.
Open this publication in new window or tab >>A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts
Show others...
2023 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 17, no Suppl. 1, p. I314-I315, article id P154Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2023
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-107219 (URN)000960367600284 ()
Conference
18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023
Available from: 2023-07-31 Created: 2023-07-31 Last updated: 2024-01-02Bibliographically approved
Hylén, U., Särndahl, E., Bejerot, S., Humble, M. B., Hyötyläinen, T., Salihovic, S. & Eklund, D. (2023). Alterations in inflammasome-related immunometabolites in individuals with severe psychiatric disorders. BMC Psychiatry, 23(1), Article ID 268.
Open this publication in new window or tab >>Alterations in inflammasome-related immunometabolites in individuals with severe psychiatric disorders
Show others...
2023 (English)In: BMC Psychiatry, E-ISSN 1471-244X, Vol. 23, no 1, article id 268Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: Psychiatric disorders are common and significantly impact the quality of life. Inflammatory processes are proposed to contribute to the emergence of psychiatric disorders. In addition to inflammation, disturbances in metabolic pathways have been observed in individuals with different psychiatric disorders. A suggested key player in the interaction between inflammation and metabolism is the Nod-like receptor 3 (NLRP3) inflammasome, and NLRP3 is known to react to a number of specific metabolites. However, little is known about the interplay between these immunometabolites and the NLRP3 inflammasome in mental health disorders.

AIM: To assess the interplay between immunometabolites and inflammasome function in a transdiagnostic cohort of individuals with severe mental disorders.

METHODS: Mass spectrometry-based analysis of selected immunometabolites, previously known to affect inflammasome function, were performed in plasma from low-functioning individuals with severe mental disorders (n = 39) and sex and aged-matched healthy controls (n = 39) using a transdiagnostic approach. Mann Whitney U test was used to test differences in immunometabolites between psychiatric patients and controls. To assess the relationship between inflammasome parameters, disease severity, and the immunometabolites, Spearman's rank-order correlation test was used. Conditional logistic regression was used to control for potential confounding variables. Principal component analysis was performed to explore immunometabolic patterns.

RESULTS: Among the selected immunometabolites (n = 9), serine, glutamine, and lactic acid were significantly higher in the patient group compared to the controls. After adjusting for confounders, the differences remained significant for all three immunometabolites. No significant correlations were found between immunometabolites and disease severity.

CONCLUSION: Previous research on metabolic changes in mental disorders has not been conclusive. This study shows that severely ill patients have common metabolic perturbations. The changes in serine, glutamine, and lactic acid could constitute a direct contribution to the low-grade inflammation observed in severe psychiatric disorders.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023
Keywords
Comorbidity, Inflammasomes, Inflammation, Mental Disorders, Metabolic pathways, Psychoneuroimmunology
National Category
Psychiatry
Identifiers
urn:nbn:se:oru:diva-105613 (URN)10.1186/s12888-023-04784-y (DOI)000975250300004 ()37076825 (PubMedID)2-s2.0-85152978734 (Scopus ID)
Funder
Knowledge Foundation, 20200017
Available from: 2023-04-21 Created: 2023-04-21 Last updated: 2024-02-23Bibliographically approved
Dunder, L., Salihovic, S., Elmståhl, S., Lind, P. M. & Lind, L. (2023). Associations between per- and polyfluoroalkyl substances (PFAS) and diabetes in two population-based cohort studies from Sweden. Journal of Exposure Science and Environmental Epidemiology, 33(5), 748-756
Open this publication in new window or tab >>Associations between per- and polyfluoroalkyl substances (PFAS) and diabetes in two population-based cohort studies from Sweden
Show others...
2023 (English)In: Journal of Exposure Science and Environmental Epidemiology, ISSN 1559-0631, E-ISSN 1559-064X, Vol. 33, no 5, p. 748-756Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) have been suggested to contribute to the development of metabolic diseases such as obesity, diabetes and non-alcoholic fatty liver disease (NAFLD). However, evidence from epidemiological studies remain divergent. The aim of the present study was to evaluate associations between PFAS exposure and prevalent diabetes in a cross-sectional analysis and fasting glucose in a longitudinal analysis.

METHODS: In 2373 subjects aged 45-75 years from the EpiHealth study, three PFAS; perfluorohexanesulfonic acid (PFHxS), perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) were analyzed in plasma together with information on prevalent diabetes. Participants in the PIVUS study (n = 1016 at baseline, all aged 70 years) were followed over 10 years regarding changes in plasma levels of six PFAS; PFHxS, PFOA, PFOS, perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid (PFUnDA), and changes in plasma levels of fasting glucose.

RESULTS: In the EpiHealth study, no overall associations could be observed between the levels of PFOA, PFOS or PFHxS and prevalent diabetes. However, there was a significant sex-interaction for PFOA (p = 0.02), and an inverse association could be seen between PFOA (on a SD-scale) and prevalent diabetes in women only (OR: 0.71, 95% CI: 0.52, 0.96, p-value: 0.02). This association showed a non-monotonic dose-response curve. In the PIVUS study, inverse relationships could be observed between the changes in levels (ln-transformed) of PFOA and PFUnDA vs the change in fasting glucose levels (ln-transformed) over 10 years (p = 0.04 and p = 0.02, respectively). As in EpiHealth, these inverse associations were significant only in women (PFOA: β: -0.03, p = 0.02, PFUnDA: β: -0.03, p = 0.03).

IMPACT: Exposure to per- and polyfluoroalkyl substances (PFAS) has been linked to unfavorable human health, including metabolic disorders such as obesity, diabetes and non-alcoholic fatty liver disease. However, results from in vivo, in vitro and epidemiological studies are incoherent. The aim of the present study was therefore to investigate associations between PFAS and diabetes in a cross-sectional study and glucose levels in a longitudinal study. Results show inverse associations in women only. Results also display non-monotonic dose response curves (i.e., that only low levels of PFOA are related to higher probability of prevalent diabetes). This suggests that sex differences and complex molecular mechanisms may underlie the observed findings. A better understanding of the factors and molecular mechanisms contributing to such differences is recognized as an important direction for future research.

CONCLUSIONS: PFOA was found to be inversely related to both prevalent diabetes and changes in plasma glucose levels among women only. Thus, our findings suggest there are sex differences in the inverse relationship of PFOA and type 2 diabetes and glucose levels.

Place, publisher, year, edition, pages
Nature Publishing Group, 2023
Keywords
Cross-sectional, Diabetes, Longitudinal, Metabolomics, Perfluoroalkyl substances (PFAS)
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:oru:diva-105191 (URN)10.1038/s41370-023-00529-x (DOI)000958477300001 ()36964247 (PubMedID)2-s2.0-85150609757 (Scopus ID)
Funder
Uppsala University
Note

Funding agency:

Uppsala University Hospital (ALF)

Available from: 2023-03-27 Created: 2023-03-27 Last updated: 2023-10-16Bibliographically approved
Marianne, H., Dunder, L., Lind, P. M., Lind, L. & Salihovic, S. (2023). Associations of perfluoroalkyl substances (PFAS) with lipid and lipoprotein profiles. Journal of Exposure Science and Environmental Epidemiology, 33(5), 757-765
Open this publication in new window or tab >>Associations of perfluoroalkyl substances (PFAS) with lipid and lipoprotein profiles
Show others...
2023 (English)In: Journal of Exposure Science and Environmental Epidemiology, ISSN 1559-0631, E-ISSN 1559-064X, Vol. 33, no 5, p. 757-765Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Perfluoroalkyl substances (PFAS) are man-made chemicals with unique properties that are widely distributed in humans and the environment. Recent studies suggest that PFAS are involved in cholesterol metabolism, however, the mechanisms underlying the associations are poorly understood.

OBJECTIVE: We aimed to evaluate associations of plasma PFAS with detailed lipid and lipoprotein subfractions in an adult population of men and women.

METHODS: We measured concentrations of cholesterol and triglycerides in lipoprotein subfractions, apolipoprotein subclasses, as well as fatty acid and different phospholipid measures, using serum proton nuclear magnetic resonance (1H-NMR), and four plasma PFAS using liquid chromatography-mass spectrometry (UHPLC-MS/MS). Measurements were available for 493 participants (all aged 50 years, 50% female). Multivariable linear regression was used to estimate the association of four PFAS with 43 different 1H-NMR measures, with adjustment for body mass index (BMI), smoking, education, and physical activity.

RESULTS: We found that perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorodecanoic acid (PFDA), but not perfluorohexanesulfonate (PFHxS), concentrations were consistently positively associated with concentrations of cholesterol in lipoprotein subfractions, apolipoproteins, as well as composite fatty acid- and phospholipid profiles. The most consistent associations were found for the relationship of PFAS with total cholesterol in intermediate-density lipoprotein (IDL), across all low-density lipoprotein (LDL) subfractions and small high-density lipoprotein (HDL). Moreover, we found weak to null evidence for an association of any of the measured 13 triglyceride lipoprotein subfractions with PFAS.

CONCLUSIONS: Our results suggest that plasma PFAS concentrations are associated with cholesterol in small HDL, IDL and all LDL subfractions, as well as apolipoproteins and composite fatty acid and phospholipid profiles but to a lesser extent with triglycerides in lipoproteins. Our findings draw attention to the need for more detailed measurements of lipids across various lipoprotein subfractions and subclasses in assessing the role of PFAS in lipid metabolism.

IMPACT: By performing an in-depth characterization of circulating cholesterol and triglycerides in lipoprotein subfractions, apolipoprotein, fatty acid, and phospholipid concentrations, this study has expanded upon the limited literature available on the associations of plasma PFAS concentrations beyond clinical routine laboratory testing for lipids.

Place, publisher, year, edition, pages
Nature Publishing Group, 2023
Keywords
Perfluoroalkyl substances, Human health, Lipoproteins, Cholesterol, Apolipoproteins, Protonnuclear magnetic resonance
National Category
Occupational Health and Environmental Health
Identifiers
urn:nbn:se:oru:diva-105443 (URN)10.1038/s41370-023-00545-x (DOI)000983832500004 ()37019983 (PubMedID)2-s2.0-85151498053 (Scopus ID)
Available from: 2023-04-14 Created: 2023-04-14 Last updated: 2023-10-16Bibliographically approved
Huang, J.-K., Chuang, Y.-S., Wu, P.-H., Tai, C.-J., Lin, J.-R., Kuo, M.-C., . . . Lin, Y.-T. (2023). Decreased levels of perfluoroalkyl substances in patients receiving hemodialysis treatment. Science of the Total Environment, 896, Article ID 165184.
Open this publication in new window or tab >>Decreased levels of perfluoroalkyl substances in patients receiving hemodialysis treatment
Show others...
2023 (English)In: Science of the Total Environment, ISSN 0048-9697, E-ISSN 1879-1026, Vol. 896, article id 165184Article in journal (Refereed) Published
Abstract [en]

Perfluoroalkyl substances (PFAS) have been reported to be harmful to multiple organs in the human body. Based on a previous study suggesting that hemodialysis (HD) may be a means of eliminating PFAS from the human body, we aimed to compare the serum PFAS concentrations of patients undergoing regular HD, patients with chronic kidney disease (CKD) and controls. Additionally, we also investigated the correlation between PFAS and biochemical data, as well as concurrent comorbidities. We recruited 301 participants who had been on maintenance dialysis for >90 days, 20 participants with stage 5 non-dialysis CKD, and 55 control participants who did not have a diagnosis of kidney disease, with a mean creatinine level of 0.77 mg/dl. Eight different PFAS, namely perfluorooctanoic acid (PFOA), total and linear perfluorooctanesulfonic acid (PFOS), perfluoroheptanoic acid (PFHpA), perfluorohexanesulfonic acid (PFHxS), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid (PFUnDA), were measured using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Spearman correlation and multivariable linear regression with 5 % false discovery rate were used to evaluate the relationships between PFAS and clinical parameters in HD patients and controls. Circulating concentrations of seven PFAS, including total and linear PFOS (T-PFOS and L-PFOS) PFDA, PFNA, PFHxS, PFOA, and PFUnDA, were significantly lower in the HD group compared to the CKD and control group. For the interplay between biochemical data and PFAS, all of the studied PFAS were positively correlated with aspartate aminotransferase, alanine aminotransferase, glucose, blood urea nitrogen, ferritin, and vitamin D in the controls, while in HD patients, the PFAS were all positively correlated with albumin, uric acid, iron, and vitamin D. These findings may offer valuable insights for future studies seeking to eliminate PFAS.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Chronic kidney disease, End-stage renal disease, Hemodialysis, PFAS, Per- and polyfluoroalkyl substances
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:oru:diva-106756 (URN)10.1016/j.scitotenv.2023.165184 (DOI)001037868600001 ()37391133 (PubMedID)2-s2.0-85163827076 (Scopus ID)
Note

Funding agencies:

Ministry of Science and Technology, Taiwan MOST 107-2314-B-037-098-MY3 MOST 111-2314-B-037-032-MY3

Kaohsiung Medical University Hospital, Taiwan KMUH111-1M60 NHRIKMU-111-I003 NHRIKMU-111-I003-2

Kaohsiung Medical University, Taiwan KMUH-DK (B) 110003 KMUH-DK (B) 110003-4 KMUH110-0M73 KMUH111-1R73

Available from: 2023-07-03 Created: 2023-07-03 Last updated: 2023-08-30Bibliographically approved
Salihovic, S., Nyström, N., Mathisen, C.-W. B., Andersen, S., Olbjørn, C., Perminow, G., . . . Halfvarson, J. (2023). Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease. Journal of Crohn's & Colitis, 17(Suppl. 1), I76-I77, Article ID DOP14.
Open this publication in new window or tab >>Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
Show others...
2023 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 17, no Suppl. 1, p. I76-I77, article id DOP14Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2023
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-107222 (URN)000960367600055 ()
Available from: 2023-07-31 Created: 2023-07-31 Last updated: 2023-07-31Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-5752-4196

Search in DiVA

Show all publications